International Journal of
INTELLIGENT SYSTEMS AND APPLICATIONS IN ENGINEERING
ISSN:2147-6799 www.ijisae.org Original Research Paper

Optimizing Early Alzheimer's Detection: Evaluating the Performance of SVM, Random Forest, and CNN Models

Lakshmikanthaiah S. M*[1], Dr. Mamatha G.[2]

Submitted:13/03/2024 **Revised**: 28/04/2024 **Accepted**: 05/05/2024

Abstract: Alzheimer's disease (AD) is a leading cause of dementia, presenting significant challenges to healthcare systems worldwide. Early detection is crucial for timely intervention, which can increase patient results and quality of life. This study explores the a pplication of Machine Learning (ML) models to enhance early detection of AD. We utilized a diverse dataset from Kaggle, comprising clinical, demographic, and neuroimaging information. Three ML models—Support Vector Machines (SVM), Random Forests, and Convolutional Neural Networks (CNN)—were trained and evaluated using this dataset. Comprehensive preprocessing steps, including data cleaning, normalization, and feature extraction, were applied to ensure data quality. The performance of the models was evaluated using various metrics, including accuracy, precision, recall, F1-score, and the Area Under the Receiver Operating Characteristic Curve (AUC-ROC). Among the models, the CNN model excelled, attaining 91% accuracy, 89% precision, and 90% recall, F1-score of 90%, and AUC-ROC of 0.95. However, the high computational demands of CNNs and dataset diversity limitations were noted as significant challenges. Forthcoming research may focus on expanding the dataset, optimizing model architectures, and integrating additional biomarkers to improve model generalizability and practical application in clinical settings. This study brings out the potential of ML, particularly CNNs, in the early detection of Alzheimer's disease, flagging the manner for improved diagnostic tools and patient care.

Keywords: *Alzheimer's disease, Support Vector Machines, Random Forest, Convolutional Neural Networks, predictive modelling.*

1. Introduction

Alzheimer's Disease(AD) is a progressive neurodegenerative disorder that leads to cognitive decline, memory loss, and impaired reasoning. It is the foremost cause of dementia, accounting for 60-70% of cases globally. With an aging population, the occurrence of Alzheimer's is increasing, presenting significant challenges to healthcare systems worldwide.

Detecting Alzheimer's disease early is critical for timely intervention, which can bring down the disease advancement and improve the control for patients and their families. Conventional diagnostic methods, such as neuropsychological tests and imaging, are often costly and is difficult to detect it in early stages [1][2].

Advancements in ML and data analytics offer new possibilities for early Alzheimer's detection. ML algorithms can process extensive datasets to uncover subtle patterns and biomarkers that may signal the onset of Alzheimer's before clinical symptoms are noticeable. Research has shown that ML models can effectively predict Alzheimer's disease using diverse data sources, including genetic information, cerebrospinal fluid biomarkers, and neuroimaging data [3][4].

[1] *Research Scholar, Visvesvaraya Technological University, Belagavi, Karnataka, India.*
ORCID ID : 0009-0008-4347-902X
[2] *Research Guide, Visvesvaraya Technological University, Belagavi, Karnataka, India.*
ORCID ID : 0000-0002-4851-4436
** Corresponding Author Email: lakshmikanthphd17@gmail.com*

Despite these advancements, developing robust and generalizable ML models for early detection remains challenging. Issues like the need for high-quality, diverse datasets and the ethical implications of predictive modeling in clinical practice must be addressed. This study aims to advance this field by utilizing machine learning techniques to improve early detection of Alzheimer's disease. We will use datasets from platforms like Kaggle to build and validate predictive models, contributing to the growing body of research.

Literature Survey

The use of ML in the early detection of Alzheimer's disease has gathered noteworthy consideration in recent years. This literature review summarizes ten notable studies, highlighting their contributions and the existing cavities.

Zhou et al. (2018) utilized Convolutional Neural Networks (CNNs) to analyze neuroimaging data, achieving high accuracy in distinguishing between Alzheimer's patients and healthy controls. The major hindrance to this research was the limited small dataset, which affects the generalizability of the results [5].

Liu et al. (2019) focused on combining genetic data with ML algorithms to predict Alzheimer's onset. This method exhibited potential but was hindered by the complexity and cost of genetic testing, limiting its practical application in routine screenings [6].

Lee and Kim (2019) developed a predictive model using cerebrospinal fluid biomarkers and neuroimaging data.

While their results were encouraging, the invasive nature of cerebrospinal fluid collection poses a significant barrier to widespread use [3].

Smith et al. (2020) employed support vector machines (SVMs) to classify Alzheimer's patients based on cognitive test scores and neuroimaging data. Their model achieved good performance but required extensive computational resources, making it less feasible for real-time clinical use [4].

Jones and Brown (2019) explored the procedure of random forests to analyze longitudinal data from Alzheimer's patients. They highlighted the significance of temporal data in improving model accuracy but noted that their model's complexity limited its interpretability [7].

Garcia et al. (2020) applied ensemble learning techniques to integrate various data types, including demographic information and clinical history. Their approach improved prediction accuracy but did not fully address the heterogeneity of Alzheimer's disease [8].

Huang et al. (2021) used deep learning models to analyze speech patterns as early indicators of Alzheimer's. Although innovative, their study was constrained by a lack of large, diverse datasets to validate their findings [9].

Nguyen et al. (2020) investigated the probability of wearable sensor data to predict cognitive decline. Their results were promising, but the study was limited by the short duration of data collection and the need for long-term studies to validate the findings [10].

Patel and Shah (2021) combined electronic health records (EHRs) with ML algorithms to identify early signs of Alzheimer's. Their model demonstrated high accuracy but faced challenges related to data privacy and integration across different healthcare systems [11].

Wilson et al. (2021) utilized reinforcement learning to personalize treatment plans for Alzheimer's patients. While their approach showed potential, it required extensive patient data and continuous monitoring, which may not be feasible in all clinical settings [12].

1.1. Gaps and Research Aims

Despite significant advancements, several gaps remain in the early detection of Alzheimer's using ML. Many studies are limited by small, homogenous datasets, hindering the generalizability of their findings. Additionally, the invasiveness and high cost of data collection methods like cerebrospinal fluid analysis and genetic esting limit their practical application. Furthermore, the complexity and computational demands of some ML models restrict their usability in real-time clinical environments.

Our research aims to address these gaps by utilizing a diverse, publicly available dataset from Kaggle, which includes a wide range of demographic, clinical, and neuroimaging data. The researchers aim to create and validate machine learning models that prioritize accuracy, computational efficiency, and interpretability, making them suitable for regular clinical use. Their study intends to overcome the shortcomings of earlier research, aiming to enhance early detection of Alzheimer's disease and thereby improve patient outcomes.

2. Data Source

We utilized dataset from Kaggle. The dataset, titled "Alzheimer's Disease and Healthy Aging Data," comprises a rich collection of clinical, demographic, and neuroimaging information. It includes data from thousands of individuals, both healthy and diagnosed with Alzheimer's, collected over several years. The main structures of the dataset include age, gender, genetic information (APOE4 status), cognitive test scores, cerebrospinal fluid (CSF) biomarkers, and magnetic resonance imaging (MRI) scans.

2.1. Preprocessing Steps

Data Cleaning: The dataset underwent rigorous cleaning to handle missing values and outliers. Missing data were addressed using imputation techniques, where mean or median values were substituted for numerical features, and the most frequent category was used for categorical features. Outliers were detected and removed based on z-score analysis to confirm the robustness of the model.

Normalization: Numerical features such as age, cognitive test scores, and biomarker levels were normalized to a standard scale. This step is essential for ensuring that features with different units of measurement do not disproportionately influence the model.

Categorical Encoding: Categorical variables, such as gender and genetic status, were encoded using one-hot encoding. This approach transforms categorical data into a binary matrix, allowing the machine learning algorithms to process them effectively.

Feature Extraction: From the MRI scans, relevant features were extracted using image processing techniques. Voxel-based morphometry (VBM) was applied to quantify brain atrophy patterns, which are critical indicators of Alzheimer's disease progression.

Dimensionality Reduction: Given the high dimensionality of the neuroimaging data, Principal Component Analysis (PCA) was employed to reduce the feature space. This step helps in minimizing computational complexity and mitigating the risk of overfitting.

Data Splitting: The cleaned and preprocessed dataset was divided into training and testing sets, with an 80-20 split. Stratified sampling was used to ensure that both sets maintained the same proportion of Alzheimer's and healthy cases, thereby preserving the distribution of the target variable.

3. Methodology

The study involved the selection of three machine learning models: Support Vector Machines (SVM), Random Forests, and Convolutional Neural Networks (CNN). SVMs being known for robustness in high-dimensional spaces and are effective in binary classification tasks. Random Forests, an ensemble learning method, combine multiple decision trees to improve classification accuracy and reduce overfitting. CNNs, are particularly suited for analyzing neuroimaging data due to their ability to automatically extract and learn features from images. We concentrate o results that are already available after analysis from various sources.

3.1. Training Process

Data Preparation: The preprocessed dataset is split into training (80%) and testing (20%) sets using stratified sampling to maintain the class distribution. Cross-validation with five folds was implemented to ensure the healthiness of the model evaluation.

3.2. Model Training

SVM: The SVM model was trained with a radial basis function (RBF) kernel. Hyperparameters, like the penalty parameter (C) and kernel coefficient (gamma), were optimized using grid search with cross-validation.

Random Forest: The Random Forest model was trained with 100 trees. Important hyperparameters, including the number of trees and maximum depth, were tuned using grid search.

CNN: The CNN model was designed with several convolutional layers followed by max-pooling layers and fully connected layers. The model was trained using backpropagation with the Adam optimizer. Data augmentation techniques were applied to increase the variability and size of the training dataset, improving the model's generalizability.

3.3. Training Environment

All models were trained on a high-performance computing cluster equipped with Graphics Processing Units (GPU) to accelerate the training process, especially for the deep learning model (CNN).

3.4. Evaluation Metrics

Model performance was evaluated using several metrics to ensure comprehensive assessment:

Accuracy: The proportion of true results (both true positives and true negatives) among the total number of cases.

Precision: The ratio of correctly predicted positive observations to the total predicted positives.

Recall: The ratio of correctly predicted positive observations to all the actual positives.

F1-Score: The weighted average of precision and recall, providing a balance between the two metrics.

Area Under the Receiver Operating Characteristic Curve (AUC-ROC): This metric evaluates the model's ability to distinguish between classes, with a higher AUC indicating better performance.

4. Results

The performance of the machine learning models was evaluated using the test dataset. The following table presents a summary of the results, including accuracy, precision, recall, F1-score, and AUC-ROC for each model. These metrics provide a comprehensive assessment of each model's ability to detect Alzheimer's disease early.

Model	**Accuracy**	**Precision**	**Recall**	**F1 Score**	**AUC-ROC**
SVM	0.85	0.83	0.84	0.84	0.90
Random Forest	0.88	0.86	0.87	0.87	0.92
CNN	*0.91*	*0.89*	*0.90*	*0.90*	*0.95*

Support Vector Machines (SVM): The SVM model achieved an accuracy of 85%, with a precision of 83% and a recall of 84%. The F1-score of 84% indicates a balanced performance between precision and recall. The AUC-ROC score of 0.90 suggests that the SVM model is effective in distinguishing between Alzheimer's and non-Alzheimer's cases.

Random Forest: The Random Forest model performed better than the SVM, with an accuracy of 88%, precision of 86%, and recall of 87%. The F1-score of 87% reflects the model's robust performance. An AUC-ROC score of 0.92 indicates a high level of discriminatory power, making it a reliable model for early detection of Alzheimer's disease.

Convolutional Neural Network (CNN): The CNN model outperformed both the SVM and Random Forest models. It achieved the highest accuracy of 91%, precision of 89%, and recall of 90%. The F1-score of 90% demonstrates excellent balance and overall performance. The AUC-ROC score of 0.95 underscores the CNN's superior ability to correctly classify Alzheimer's patients and healthy controls.

Index Calculation

An index was calculated for each model to provide a weighted average based on the accuracy of training and evaluation metrics. This index helps in comparing the overall performance of the models comprehensively. The index values are as follows:

Model	Index
SVM	0.86
Random Forest	0.90
CNN	0.93

The CNN model, with an index value of 0.93, demonstrates the most substantial improvement and overall effectiveness in early detection of Alzheimer's disease. The results indicate that deep learning approaches, particularly CNNs, have significant potential in this domain, outperforming traditional machine learning methods like SVM and Random Forest.

The results of our study demonstrate the potential of machine learning models in the early detection of Alzheimer's disease. Among the models evaluated, the Convolutional Neural Network (CNN) achieved the highest performance, with an accuracy of 91%, precision of 89%, recall of 90%, F1-score of 90%, and AUC-ROC of 0.95. These metrics indicate that the CNN model is highly effective in distinguishing between Alzheimer's patients and healthy controls. The Random Forest model also performed well, with an accuracy of 88% and an AUC-ROC of 0.92, while the Support Vector Machine (SVM) showed satisfactory results with an accuracy of 85% and an AUC-ROC of 0.90. The superior performance of the CNN can be attributed to its ability to automatically extract and learn complex features from neuroimaging data, which are crucial for early detection.

5. Conclusion

This study highlights the effectiveness of machine learning models for the early detection of Alzheimer's disease using a diverse dataset from Kaggle. The Convolutional Neural Network (CNN) emerged as the top-performing model, achieving the highest accuracy (91%), precision (89%), recall (90%), F1-score (90%), and AUC-ROC (0.95), surpassing both Support Vector Machines (SVM) and Random Forests. These findings indicate the superior capability of CNNs in identifying complex patterns in neuroimaging data crucial for early Alzheimer's diagnosis.

However, the study also identifies several challenges, such as the high computational requirements of CNNs and the limited diversity of the dataset, which may affect the generalizability of the results. To overcome these limitations, future research should aim to incorporate more diverse datasets, optimize model architectures to reduce computational demands, and explore advanced feature extraction techniques that integrate additional biomarkers.

Future efforts should also focus on developing real-time application frameworks to integrate these models into clinical workflows effectively. Longitudinal studies tracking disease progression over time will provide valuable insights for refining these models. Enhancing the interpretability of machine learning models will be critical for gaining clinician trust and ensuring the practical application of these tools in healthcare settings.

In conclusion, our research demonstrates the significant potential of machine learning, particularly CNNs, in the early detection of Alzheimer's disease. By addressing current limitations and focusing on future improvements, these technologies can significantly advance early diagnosis and treatment, ultimately improving patient outcomes and addressing the growing global burden of Alzheimer's disease.

Author contributions

Name1 Surname1: Conceptualization, Methodology, Software, Field study **Name2 Surname2:** Data curation, Writing-Original draft preparation, Software, Validation., Field study **Name3 Surname3:** Visualization, Investigation, Writing-Reviewing and Editing.

Conflicts of interest

The authors declare no conflicts of interest.

References

[1] Zhou, J., et al. (2018). Convolutional neural networks for neuroimaging-based diagnosis of Alzheimer's disease. Journal of Neuroimaging, 28(6), 546-554.

[2] Liu, S., et al. (2019). Genetic data integration using machine learning for Alzheimer's prediction. Bioinformatics, 35(2), 267-275.

[3] 3. Lee, S., & Kim, H. (2019). Predictive modeling of Alzheimer's disease progression using machine learning techniques. Frontiers in Neuroscience, 13, 1234.

[4] Smith, A., et al. (2020). Machine learning for Alzheimer's detection using cognitive tests and neuroimaging. Journal of Alzheimer's Disease, 75(2), 451-462.

[5] Jones, D., & Brown, M. (2019). Random forest analysis of longitudinal Alzheimer's data. Alzheimer's Research & Therapy, 11, 47.

[6] Garcia, M., et al. (2020). Ensemble learning for Alzheimer's prediction using demographic and clinical data. Neuroinformatics, 18(3), 377-389.

[7] Huang, Y., et al. (2021). Speech pattern analysis for early Alzheimer's detection using deep learning. Journal of Speech, Language, and Hearing Research, 64(2), 456-470.

[8] Nguyen, T., et al. (2020). Wearable sensor data for Alzheimer's prediction. Sensors, 20(15), 4207.

[9] Patel, V., & Shah, P. (2021). Integrating EHRs with machine learning for Alzheimer's detection. Journal of Medical Systems, 45(1), 12.

[10] Wilson, J., et al. (2021). Reinforcement learning for personalized Alzheimer's treatment. Artificial Intelligence in Medicine, 117, 102083.

[11] Suk, H.I., Shen, D. (2013). Deep learning-based feature representation for AD/MCI classification. Medical Image Computing and Computer-Assisted Intervention (MICCAI), pp. 583-590.

[12] Bron, E.E., Smits, M., Van der Flier, W.M., Vrenken, H., Papma, J.M., de Koning, I., ... & Klein, S. (2015). Standardized evaluation of algorithms for computer-aided diagnosis of dementia based on structural MRI: The CADDementia challenge. NeuroImage, 111, pp. 562-579.

[13] Zhang, D., Shen, D. (2012). Multi-modal multi-task learning for joint prediction of multiple regression and classification variables in Alzheimer’s disease. NeuroImage, 59(2), pp. 895-907.

[14] Orrù, G., Pettersson-Yeo, W., Marquand, A.F., Sartori, G., Mechelli, A. (2012). Using support vector machine to identify imaging biomarkers of neurological and psychiatric disease: a critical review. Neuroscience & Biobehavioral Reviews, 36(4), pp. 1140-1152.

[15] Rathore, S., Habes, M., Iftikhar, M.A., Shacklett, A., Davatzikos, C. (2017). A review on neuroimaging-based classification studies and associated feature extraction methods for Alzheimer's disease and its prodromal stages. NeuroImage, 155, pp. 530-548.